In this episode, we present the second part of our conversation with the authors of the scouting reports for the teams in the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  Plus, we highlight Q&As from theMednet.org about the T'd Up T-Cells teams AND record an interview with Dr. Bill St. Clair, the first author of the phase 2 dazodalibep study.  It's a long episode because there's so much content!Links to the Q&As from theMednet.org discussed in this episode:What is your approach to managing sicca symptoms in patients not responding or not tolerating conservative measures, pilocarpine, and cevimeline?What is your approach to immunomodulatory treatment in patients with Sjogren’s syndrome who have active serologies (i.e. elevated ESR, hypergammaglobulinemia, hypocomplementemia) but minimal symptoms?What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?What factors drive you to prioritize T vs B cell inhibition when choosing therapies for patients with refractory SLE?To learn more about RheumMadness:https://sites.duke.edu/rheummadness/Subscribe to our newsletter:https://lists.duke.edu/sympa/subscribe/rheummadnessFind us on social media:Bluesky: @rheummadness.bsky.socialInstagram: https://www.instagram.com/rheummadness/X: Follow #RheumMadnessIntro/outro music: Cheery Monday by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3495-cheery-mondayLicense: http://creativecommons.org/licenses/by/4.0/

Ver todos los episodios